Drugs / Humanized TNFα monoclonal antibody
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02460393 | May → Nov 2015 | rheumatoid arthritis | Shenyang Sunshine Pharmaceutical Co., LTD. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04988425 | Sep 2022 → Aug 2023 | spinal cord injury | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Humanized TNFα monoclonal antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02460393 ↗ |
| Known as | TNFα Monoclonal Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04988425 ↗ |
| Action | Inhibit | “TNF-α inhibitor” NCT04988425 ↗ |
| Modality | Monoclonal antibody | “humanized TNFα monoclonal antibody” NCT02460393 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT02460393 ↗ |